

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shaanxi Micot Pharmaceutical Technology Co., Ltd.
陝西麥科奧特醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02335)

VOLUNTARY ANNOUNCEMENT

**INCLUSION IN THE STOCK LIST UNDER
THE STOCK CONNECT PROGRAM
(SHANGHAI-HONG KONG STOCK CONNECT AND
SHENZHEN-HONG KONG STOCK CONNECT)**

The board of directors (the “**Board**”) of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that according to the announcements from the Shanghai Stock Exchange and the Shenzhen Stock Exchange on September 4, 2026 and September 7, 2026, respectively, the H shares of the Company (the “**Shares**”) have been included in the eligible shares list of the Stock Connect Program (the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect) with effect from September 7, 2026. The inclusion of the Shares in the Stock Connect Program allows eligible investors in the Chinese Mainland to trade in the Shares through the Shanghai Stock Exchange and the Shenzhen Stock Exchange.

The Company believes that the inclusion of the Shares as eligible securities under the Stock Connect Program demonstrates market recognition of the Company’s investment value and growth prospects. The Company expects the inclusion of the Shares as eligible securities will help further expand the shareholder base of the Company, increase the trading liquidity of the Shares, and support the innovation-driven and sustainable growth of the Company in the long term.

ABOUT THE STOCK CONNECT PROGRAM

The Shanghai Stock Exchange, the Shenzhen Stock Exchange and the Stock Exchange of Hong Kong Limited are technically connected, enabling investors in the Chinese Mainland and the Hong Kong Special Administrative Region to trade eligible stocks listed on the respective stock exchanges through their local securities firms or brokers.

By Order of the Board

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Dr. Wang Bing

Chairman, Chief Executive Officer and Executive Director

Xi'an, Shaanxi, the PRC, 7 September 2026

As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as independent non-executive Directors.